257 related articles for article (PubMed ID: 33172975)
1. Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling.
Dwyer AR; Kerkvliet CP; Krutilina RI; Playa HC; Parke DN; Thomas WA; Smeester BA; Moriarity BS; Seagroves TN; Lange CA
Mol Cancer Res; 2021 Feb; 19(2):329-345. PubMed ID: 33172975
[TBL] [Abstract][Full Text] [Related]
2. Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Regan Anderson TM; Ma S; Perez Kerkvliet C; Peng Y; Helle TM; Krutilina RI; Raj GV; Cidlowski JA; Ostrander JH; Schwertfeger KL; Seagroves TN; Lange CA
Mol Cancer Res; 2018 Nov; 16(11):1761-1772. PubMed ID: 29991529
[TBL] [Abstract][Full Text] [Related]
3. Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.
Regan Anderson TM; Ma SH; Raj GV; Cidlowski JA; Helle TM; Knutson TP; Krutilina RI; Seagroves TN; Lange CA
Cancer Res; 2016 Mar; 76(6):1653-63. PubMed ID: 26825173
[TBL] [Abstract][Full Text] [Related]
4. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.
Lofgren KA; Ostrander JH; Housa D; Hubbard GK; Locatelli A; Bliss RL; Schwertfeger KL; Lange CA
Breast Cancer Res; 2011 Sep; 13(5):R89. PubMed ID: 21923922
[TBL] [Abstract][Full Text] [Related]
5. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression.
Regan Anderson TM; Peacock DL; Daniel AR; Hubbard GK; Lofgren KA; Girard BJ; Schörg A; Hoogewijs D; Wenger RH; Seagroves TN; Lange CA
Cancer Res; 2013 Sep; 73(18):5810-20. PubMed ID: 23928995
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid receptors are required effectors of TGFβ1-induced p38 MAPK signaling to advanced cancer phenotypes in triple-negative breast cancer.
Perez Kerkvliet C; Dwyer AR; Diep CH; Oakley RH; Liddle C; Cidlowski JA; Lange CA
Breast Cancer Res; 2020 May; 22(1):39. PubMed ID: 32357907
[TBL] [Abstract][Full Text] [Related]
7. The putative endogenous AHR ligand ITE reduces JAG1 and associated NOTCH1 signaling in triple negative breast cancer cells.
Piwarski SA; Thompson C; Chaudhry AR; Denvir J; Primerano DA; Fan J; Salisbury TB
Biochem Pharmacol; 2020 Apr; 174():113845. PubMed ID: 32032581
[TBL] [Abstract][Full Text] [Related]
8. 3,3'-Diindolylmethane modulates aryl hydrocarbon receptor of esophageal squamous cell carcinoma to reverse epithelial-mesenchymal transition through repressing RhoA/ROCK1-mediated COX2/PGE
Zhu P; Yu H; Zhou K; Bai Y; Qi R; Zhang S
J Exp Clin Cancer Res; 2020 Jun; 39(1):113. PubMed ID: 32546278
[TBL] [Abstract][Full Text] [Related]
9. Rhophilin-associated tail protein 1 promotes migration and metastasis in triple negative breast cancer via activation of RhoA.
Liu Q; Huang X; Li Q; He L; Li S; Chen X; Ouyang Y; Wang X; Lin C
FASEB J; 2020 Aug; 34(8):9959-9971. PubMed ID: 32427399
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Ah Receptor (AhR) increases the aggressiveness of TNBC cells and 11-Cl-BBQ-activated AhR inhibits their growth.
Elson DJ; Nguyen BD; Korjeff NA; Wilferd SF; Puig-Sanvicens V; Sang Jang H; Bernales S; Chakravarty S; Belmar S; Ureta G; Finlay D; Plaisier CL; Kolluri SK
Biochem Pharmacol; 2023 Sep; 215():115706. PubMed ID: 37506922
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor α and aryl hydrocarbon receptor independent growth inhibitory effects of aminoflavone in breast cancer cells.
Brinkman AM; Wu J; Ersland K; Xu W
BMC Cancer; 2014 May; 14():344. PubMed ID: 24885022
[TBL] [Abstract][Full Text] [Related]
12. Putative tumor suppressor cytoglobin promotes aryl hydrocarbon receptor ligand-mediated triple negative breast cancer cell death.
Rowland LK; Campbell PS; Mavingire N; Wooten JV; McLean L; Zylstra D; Thorne G; Daly D; Boyle K; Whang S; Unternaehrer J; Brantley EJ
J Cell Biochem; 2019 Apr; 120(4):6004-6014. PubMed ID: 30450577
[TBL] [Abstract][Full Text] [Related]
13. Aryl hydrocarbon receptor mediates Jak2/STAT3 signaling for non-small cell lung cancer stem cell maintenance.
Xiong J; Zhang X; Zhang Y; Wu B; Fang L; Wang N; Yi H; Chang N; Chen L; Zhang J
Exp Cell Res; 2020 Nov; 396(1):112288. PubMed ID: 32941808
[TBL] [Abstract][Full Text] [Related]
14. PTK6 Inhibition Suppresses Metastases of Triple-Negative Breast Cancer via SNAIL-Dependent E-Cadherin Regulation.
Ito K; Park SH; Nayak A; Byerly JH; Irie HY
Cancer Res; 2016 Aug; 76(15):4406-17. PubMed ID: 27302163
[TBL] [Abstract][Full Text] [Related]
15. Breast Tumour Kinase (Brk/PTK6) Contributes to Breast Tumour Xenograft Growth and Modulates Chemotherapeutic Responses In Vitro.
Burmi RS; Box GM; Wazir U; Hussain HA; Davies JA; Court WJ; Eccles SA; Jiang WG; Mokbel K; Harvey AJ
Genes (Basel); 2022 Feb; 13(3):. PubMed ID: 35327957
[TBL] [Abstract][Full Text] [Related]
16. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
17. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.
Castro NE; Lange CA
Breast Cancer Res; 2010; 12(4):R60. PubMed ID: 20687930
[TBL] [Abstract][Full Text] [Related]
18. Diaphanous-related formin-3 overexpression inhibits the migration and invasion of triple-negative breast cancer by inhibiting RhoA-GTP expression.
Jiang J
Biomed Pharmacother; 2017 Oct; 94():439-445. PubMed ID: 28779705
[TBL] [Abstract][Full Text] [Related]
19. In Silico Screening of Multi-Domain Targeted Inhibitors for PTK6: A Strategy Integrating Drug Repurposing and Consensus Docking.
Zhou Y; Wong MW
Pharmaceuticals (Basel); 2023 Dec; 17(1):. PubMed ID: 38256893
[TBL] [Abstract][Full Text] [Related]
20. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
